Following the FDA’s recent approval of Handa Pharmaceuticals’ novel formulation of Cabometyx, analysts are weighing the implications for Exelixis, the original developer of the drug. This marks the third successful reformulation for Handa, highlighting a strategic pivot that has garnered regulatory success. The approval is significant as it opens the door for Handa to compete more aggressively in the oncology market, potentially reshaping the landscape for Cabometyx’s usage.
However, industry experts predict that the threat to Exelixis will be limited. The existing market presence and established brand loyalty of Exelixis, coupled with the specific therapeutic niche that Cabometyx occupies, suggest that Handa’s reformulation may not drastically alter market dynamics. As such, while Handa’s success is noteworthy, it may not lead to a substantial decline in Exelixis’s market share, allowing the original developer to maintain its foothold in the oncology sector.
Start your 7-day trial and see what the database can do →
